Literature DB >> 8093352

Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro.

A al-Katib1, R M Mohammad, M Dan, M E Hussein, A Akhtar, G R Pettit, L L Sensenbrenner.   

Abstract

The phorbol esters induce differentiation of chronic lymphocytic leukemia (CLL) cells. Clinical use of this observation has been hampered by the fact that phorbol esters are also tumor promoters. In this study we demonstrate that another protein kinase C activator, without tumor promoting activity, has similar effects on CLL cells. Fresh leukemic cells from the peripheral blood of 13 patients with CLL were isolated and cultured in the absence (control) or presence of Bryostatin 1 or 12-0-tetradecanoylphorbol 13-acetate (TPA). Aliquots of cells were then analyzed after 24, 72 and 120 hours for morphological changes, acid phosphatase (ACP) and the co-expression of two hairy cell-associated surface antigens, CD22 and CD11c, by flow cytometry. Bryostatin 1 induced changes in shape and morphology similar to TPA, with adherence and increase in cell size, abundant cytoplasm and irregular cytoplasmic membrane. Both agents induced a statistically significant increase in the expression of CD22 and CD11c compared with control (p < 0.0008). There was no significant difference between the two agents in the degree of expression of these two markers. Both agents also induced ACP that was tartrate resistant (TRAP). These changes indicate that Bryostatin is as effective as TPA in inducing further differentiation of CLL cells to a hairy cell stage.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093352

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  9 in total

1.  The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.

Authors:  Viola Biberacher; Thomas Decker; Madlen Oelsner; Michaela Wagner; Christian Bogner; Burkhard Schmidt; Robert J Kreitman; Christian Peschel; Ira Pastan; Christian Meyer Zum Büschenfelde; Ingo Ringshausen
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

Review 2.  Management of chronic lymphocytic leukaemia.

Authors:  N Kalil; B D Cheson
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

Review 3.  New drug development in non-Hodgkin lymphomas.

Authors:  B D Cheson
Journal:  Curr Oncol Rep       Date:  2001-05       Impact factor: 5.075

Review 4.  Protein kinase C targeting in antineoplastic treatment strategies.

Authors:  W D Jarvis; S Grant
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 5.  Review of survival analyses published in cancer journals.

Authors:  D G Altman; B L De Stavola; S B Love; K A Stepniewska
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

6.  Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line.

Authors:  Lingyan Wang; Yue Zhang; Eden Anderson; Adam Lamble; Rimas J Orentas
Journal:  Front Immunol       Date:  2022-02-09       Impact factor: 7.561

7.  A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

Authors:  G C Jayson; D Crowther; J Prendiville; A T McGown; C Scheid; P Stern; R Young; P Brenchley; J Chang; S Owens
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

Review 8.  Protein kinase C in cellular transformation: a valid target for therapy?

Authors:  Anuradha Tarafdar; Alison M Michie
Journal:  Biochem Soc Trans       Date:  2014-12       Impact factor: 5.407

9.  Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy.

Authors:  Clayton Hardman; Stephen Ho; Akira Shimizu; Quang Luu-Nguyen; Jack L Sloane; Mohamed S A Soliman; Matthew D Marsden; Jerome A Zack; Paul A Wender
Journal:  Nat Commun       Date:  2020-04-20       Impact factor: 17.694

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.